Logistics of therapy with the ibritumomab tiuxetan regimen.
Radioimmunotherapy is an important new modality for treating patients with B-cell non-Hodgkin's lymphoma (NHL). Clinical trials have shown the safety and efficacy of agents that deliver radiation directly to malignant cells by attaching the (131)I or (90)Y radionuclide to monoclonal antibodies against CD20. In clinical trials, (90)Y ibritumomab tiuxetan has produced rates of response as high as 83% in patients with relapsed or refractory CD20+ NHL. The ibritumomab tiuxetan regimen is conveniently given in an outpatient setting over the course of 7-9 days. This article describes the logistics for initiating treatment, coordinating a multidisciplinary team, identifying eligible patients, and delivering the imaging and therapeutic doses of ibritumomab tiuxetan. The standard radiation safety procedures to protect family members and healthcare professionals involved in the care of patients treated with (90)Y ibritumomab tiuxetan are also reviewed. Treatment with the ibritumomab tiuxetan regimen involves only standard precautions needed to minimize radiation exposure to other persons.
Meredith
Ruby F
RF
Department of Radiation Oncology, University of Alabama Medical Center, Birmingham, AL, USA. rmeredith@uabmc.edu
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology; D004334:Drug Administration Schedule; D006283:Health Physics / Q000592:standards; D006801:Humans; D008006:Licensure, Hospital; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy*; D010348:Patient Care Team; D018579:Patient Selection; D011835:Radiation Protection; D016499:Radioimmunotherapy / Q000379:methods*; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan